{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:58:10Z","timestamp":1760151490325,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Primary cutaneous CD30+ lymphoproliferative disorders include primary cutaneous anaplastic large cell lymphoma (pcALCL) and lymphomatoid papulosis. The prognosis of the disease is usually excellent but, in a minority of cases, it presents with extracutaneous involvement and aggressive behavior. The case we present\u2014relapsed after surgical excision, immunosuppressive therapy, and conventional chemotherapy\u2014is the first one treated with Autologous Stem Cell transplant followed by Brentuximab Vedotin consolidation, a scheme already used for high risk Hodgkin Lymphoma.<\/jats:p>","DOI":"10.3390\/hematolrep14020010","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T22:08:06Z","timestamp":1648073286000},"page":"61-66","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-0663","authenticated-orcid":false,"given":"Luca","family":"Guarnera","sequence":"first","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-3321","authenticated-orcid":false,"given":"Federico","family":"Meconi","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pocci","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito Mario","family":"Rapisarda","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annagiulia","family":"Zizzari","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4691-9381","authenticated-orcid":false,"given":"Cosimo","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livio","family":"Pupo","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3711-2714","authenticated-orcid":false,"given":"Lucia","family":"Anemona","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cantonetti","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3324\/haematol.2018.197152","article-title":"CD30-positive Primary Cutaneous Lymphoproliferative Disorders: Molecular Alterations and Targeted Therapies","volume":"104","author":"Onaindia","year":"2019","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and Secondary Cutaneous CD30+ Lymphoproliferative Disorders: A Report from the Dutch Cutaneous Lymphoma Group on the Long-Term Follow-Up Data of 219 Patients and Guidelines for Diagnosis and Treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.2012.065664","article-title":"ALK-positive Anaplastic Large Cell Lymphoma Limited to the Skin: Clinical, Histopathological and Molecular Analysis of 6 Pediatric Cases. A Report from the ALCL99 Study","volume":"98","author":"Oschlies","year":"2013","journal-title":"Haematologica"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","article-title":"Genome-wide analysis reveals recurrent structural abnormalities of TP63 and Other p53-related Genes in Peripheral T-cell Lymphomas","volume":"120","author":"Vasmatzis","year":"2012","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/modpathol.2009.196","article-title":"CDKN2A-CDKN2B Deletion Defines an Aggressive Subset of Cutaneous T-cell Lymphoma","volume":"23","author":"Laharanne","year":"2010","journal-title":"Mod. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1600-0560.2007.00971.x","article-title":"Cutaneous Lymphocyte Antigen Expression in Benign and Neoplastic Cutaneous B- And T-cell Lymphoid Infiltrates","volume":"35","author":"Magro","year":"2008","journal-title":"J. Cutan. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2559.1992.tb00343.x","article-title":"Differential Expression of the HECA-452 Antigen (Cutaneous Lymphocyte Associated Antigen, CLA) in Cutaneous and Non-Cutaneous T-cell Lymphomas","volume":"21","author":"Noorduyn","year":"1992","journal-title":"Histopathology"},{"key":"ref_9","first-page":"1893","article-title":"TIA-1 Expression in Lymphoid Neoplasms. Identification of Subsets with Cytotoxic T Lymphocyte or Natural Killer Cell Differentiation","volume":"150","author":"Felgar","year":"1997","journal-title":"Am. J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1067\/mjd.2002.121355","article-title":"Practical evaluation and management of cutaneous lymphoma","volume":"46","author":"Fung","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020","volume":"18","author":"Horwitx","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_12","first-page":"v108","article-title":"Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Gaulard","year":"2015","journal-title":"Ann Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jdv.16006","article-title":"Prognostic Factors in Patients with Primary Cutaneous Anaplastic Large Cell Lymphoma: A Multicentric, Retrospective Analysis of the Spanish Group of Cutaneous Lymphoma","volume":"34","author":"Combalia","year":"2020","journal-title":"J. Eur. Arcad. Dermatol. Venerol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab Vedotin or Physician\u2019s Choice in CD30-positive Cutaneous T-cell Lymphoma (ALCANZA): An International, Open-Label, Randomised, Phase 3, Multicentre Trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0190-9622(03)02484-8","article-title":"D30+ Cutaneous Lymphoproliferative Disorders: The Stanford Experience in Lymphomatoid Papulosis and Primary Cutaneous Anaplastic Large Cell Lymphoma","volume":"49","author":"Liu","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/PAP.0000000000000047","article-title":"Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous","volume":"22","author":"Xing","year":"2015","journal-title":"Adv. Anat. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1346-8138.2007.00330.x","article-title":"Successful Treatment for Recurrence of Primary Cutaneous Anaplastic Large-Cell Lymphoma in Elderly Patient with Etoposide, Mitoxantrone, Cyclophosphamide, Vincristine, Prednisolone and Bleomycin (VNCOP-B) Therapy","volume":"34","author":"Isogai","year":"2007","journal-title":"J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5045\/br.2017.52.4.243","article-title":"Brentuximab Vedotin: Cinical updates and practical guidance","volume":"52","author":"Yi","year":"2017","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/bjd.18806","article-title":"Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides","volume":"182","author":"Battistella","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-09-0162","article-title":"A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders","volume":"15","author":"Duvic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowtiz","year":"2015","journal-title":"Lancet"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/14\/2\/10\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:41:19Z","timestamp":1760136079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/14\/2\/10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["hematolrep14020010"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep14020010","relation":{},"ISSN":["2038-8330"],"issn-type":[{"type":"electronic","value":"2038-8330"}],"subject":[],"published":{"date-parts":[[2022,3,23]]}}}